At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
UNCY Unicycive Therapeutics, Inc.
Closed Mourning Day 01-08 16:00:00 EST
0.7449
-0.0329
-4.23%
盘后0.7300
-0.0149-2.00%
19:42 EST
High0.7802
Low0.7168
Vol1.65M
Open0.7800
D1 Closing0.7778
Amplitude8.14%
Mkt Cap77.32M
Tradable Cap45.78M
Total Shares103.80M
T/O1.23M
T/O Rate2.69%
Tradable Shares61.45M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Positive Buy Recommendation for Unicycive Therapeutics Driven by Promising Trial Results and Revenue Forecasts
Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (Nda) for Oxylanthanum Carbonate (Olc) for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease on Dialysis
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.